Express Pharma

Gilead Sciences to support expansion of local production capacity of  Remdesivir  in India 

Gilead will donate a minimum of 450,000 vials of Veklury to the Government of India

0 463

Gilead Sciences announced that in response to the rapid increase in COVID-19 cases in India, the company is providing its voluntary licensing partners with technical assistance, support for the addition of new local manufacturing facilities and the donation of active pharmaceutical ingredient (API) to rapidly scale up production of remdesivir. Remdesivir is approved in India for restricted emergency use for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalised with severe disease. In addition to providing support to its licensees to expand their local manufacturing capacity, Gilead will also donate at least 450,000 vials of Veklury (remdesivir) to help address the immediate needs of Indian patients.

“The recent surge of COVID-19 cases in India is having a devastating impact on communities and has created unprecedented pressure on health systems. We are committed to doing our part to help tackle this crisis. Our immedi